These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 20651059)

  • 1. Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial.
    Peña C; Lathia C; Shan M; Escudier B; Bukowski RM
    Clin Cancer Res; 2010 Oct; 16(19):4853-63. PubMed ID: 20651059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: analysis from the treatment approaches in renal cancer global evaluation trial (TARGET).
    Choueiri TK; Cheng S; Qu AQ; Pastorek J; Atkins MB; Signoretti S
    Urol Oncol; 2013 Nov; 31(8):1788-93. PubMed ID: 23141780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.
    Escudier B; Eisen T; Stadler WM; Szczylik C; Oudard S; Staehler M; Negrier S; Chevreau C; Desai AA; Rolland F; Demkow T; Hutson TE; Gore M; Anderson S; Hofilena G; Shan M; Pena C; Lathia C; Bukowski RM
    J Clin Oncol; 2009 Jul; 27(20):3312-8. PubMed ID: 19451442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy.
    Choueiri TK; Regan MM; Rosenberg JE; Oh WK; Clement J; Amato AM; McDermott D; Cho DC; Atkins MB; Signoretti S
    BJU Int; 2010 Sep; 106(6):772-8. PubMed ID: 20230385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of the co-expression of carbonic anhydrase IX and vascular endothelial growth factor in patients with clear cell renal cell carcinoma.
    Phuoc NB; Ehara H; Gotoh T; Nakano M; Kamei S; Deguchi T; Hirose Y
    Oncol Rep; 2008 Sep; 20(3):525-30. PubMed ID: 18695901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma.
    Motzer RJ; Hutson TE; Hudes GR; Figlin RA; Martini JF; English PA; Huang X; Valota O; Williams JA
    Cancer Chemother Pharmacol; 2014 Oct; 74(4):739-50. PubMed ID: 25100134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective evaluation of serum tissue inhibitor of metalloproteinase 1 and carbonic anhydrase IX in correlation to circulating tumor cells in patients with metastatic breast cancer.
    Müller V; Riethdorf S; Rack B; Janni W; Fasching PA; Solomayer E; Aktas B; Kasimir-Bauer S; Zeitz J; Pantel K; Fehm T;
    Breast Cancer Res; 2011 Jul; 13(4):R71. PubMed ID: 21745383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma.
    Zurita AJ; Jonasch E; Wang X; Khajavi M; Yan S; Du DZ; Xu L; Herynk MH; McKee KS; Tran HT; Logothetis CJ; Tannir NM; Heymach JV
    Ann Oncol; 2012 Jan; 23(1):46-52. PubMed ID: 21464158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 111In-bevacizumab imaging of renal cell cancer and evaluation of neoadjuvant treatment with the vascular endothelial growth factor receptor inhibitor sorafenib.
    Desar IM; Stillebroer AB; Oosterwijk E; Leenders WP; van Herpen CM; van der Graaf WT; Boerman OC; Mulders PF; Oyen WJ
    J Nucl Med; 2010 Nov; 51(11):1707-15. PubMed ID: 20956472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy.
    Stillebroer AB; Mulders PF; Boerman OC; Oyen WJ; Oosterwijk E
    Eur Urol; 2010 Jul; 58(1):75-83. PubMed ID: 20359812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy.
    Bui MH; Seligson D; Han KR; Pantuck AJ; Dorey FJ; Huang Y; Horvath S; Leibovich BC; Chopra S; Liao SY; Stanbridge E; Lerman MI; Palotie A; Figlin RA; Belldegrun AS
    Clin Cancer Res; 2003 Feb; 9(2):802-11. PubMed ID: 12576453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins.
    Deprimo SE; Bello CL; Smeraglia J; Baum CM; Spinella D; Rini BI; Michaelson MD; Motzer RJ
    J Transl Med; 2007 Jul; 5():32. PubMed ID: 17605814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantification of carbonic anhydrase IX expression in serum and tissue of renal cell carcinoma patients using enzyme-linked immunosorbent assay: prognostic and diagnostic potentials.
    Zhou GX; Ireland J; Rayman P; Finke J; Zhou M
    Urology; 2010 Feb; 75(2):257-61. PubMed ID: 19963243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma.
    Llovet JM; Peña CE; Lathia CD; Shan M; Meinhardt G; Bruix J;
    Clin Cancer Res; 2012 Apr; 18(8):2290-300. PubMed ID: 22374331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II escalation study of sorafenib in patients with metastatic renal cell carcinoma who have been previously treated with anti-angiogenic treatment.
    Mancuso A; Di Paola ED; Leone A; Catalano A; Calabrò F; Cerbone L; Zivi A; Messina C; Alonso S; Vigna L; Caristo R; Sternberg CN
    BJU Int; 2012 Jan; 109(2):200-6. PubMed ID: 22212284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
    Rini BI; Escudier B; Tomczak P; Kaprin A; Szczylik C; Hutson TE; Michaelson MD; Gorbunova VA; Gore ME; Rusakov IG; Negrier S; Ou YC; Castellano D; Lim HY; Uemura H; Tarazi J; Cella D; Chen C; Rosbrook B; Kim S; Motzer RJ
    Lancet; 2011 Dec; 378(9807):1931-9. PubMed ID: 22056247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials.
    Tran HT; Liu Y; Zurita AJ; Lin Y; Baker-Neblett KL; Martin AM; Figlin RA; Hutson TE; Sternberg CN; Amado RG; Pandite LN; Heymach JV
    Lancet Oncol; 2012 Aug; 13(8):827-37. PubMed ID: 22759480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma.
    Choueiri TK; Vaziri SA; Jaeger E; Elson P; Wood L; Bhalla IP; Small EJ; Weinberg V; Sein N; Simko J; Golshayan AR; Sercia L; Zhou M; Waldman FM; Rini BI; Bukowski RM; Ganapathi R
    J Urol; 2008 Sep; 180(3):860-5; discussion 865-6. PubMed ID: 18635227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utilizing pre-therapy clinical schema and initial CT changes to predict progression-free survival in patients with metastatic renal cell carcinoma on VEGF-targeted therapy: a preliminary analysis.
    Smith AD; Shah SN; Rini BI; Lieber ML; Remer EM
    Urol Oncol; 2013 Oct; 31(7):1283-91. PubMed ID: 21956044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma.
    Hahn OM; Yang C; Medved M; Karczmar G; Kistner E; Karrison T; Manchen E; Mitchell M; Ratain MJ; Stadler WM
    J Clin Oncol; 2008 Oct; 26(28):4572-8. PubMed ID: 18824708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.